COMPANY PROFILE: Intact Therapeutics

CED Life Science Conference 2018 - presenting at the Coulter Investment Forum

http://www.intacttherapeutics.com
Sub-sector: Pharmaceuticals/Drug Delivery
Year Founded: 2015

COMPANY PROFILE
Intact is developing a novel thermosensitive drug delivery platform for the treatment of gastrointestinal (GI) disorders. The initial target is ulcerative colitis, a form of inflammatory bowel disease (IBD) that affects millions worldwide. Today, a first line therapy for ulcerative colitis is the mesalamine enema. While mesalamine has been shown to be effective, in the enema dosage form it is difficult to retain, leading to patient adherence as low as 32%. Using gentle, biocompatible ingredients, Intact has developed a proprietary formulation that is liquid at room temperature, enhancing delivery, but then becomes a viscous, mucoadhesive gel at body temperature, enhancing retention, efficacy, and comfort. The team has completed preclinical and pilot human studies showing improved efficacy, patient retention, and comfort. The team is also exploring other indications for the platform in the GI field.

FOUNDERS/MANAGEMENT TEAM
CEO – Ravi Pamnani
Founder/Scientific Advisor – Sid Sinha, MD

KEY MILESTONES TO DATE

  • Preclinical validation in two mouse models demonstrating improved efficacy vs. standard of care
  • Published preclinical work in leading journal in field (Gastroenterology)
  • Conducted clinical evaluation in healthy volunteers to assess preference – 100% of subjects (n=19) preferred our product vs. standard of care
  • Conducted first-in-human (FIH) feasibility and safety study in 2 patients with ulcerative colitis with excellent treatment results

POWERED BY
Coulter Foundation, Stanford SPECTRUM (Clinical/Translation Science Award), Stanford Byers Center for Biodesign, Stanford Gastroenterology, Angel Funding

CONTACT
Ravi Pamnani
ravi@intacttherapeutics.com
Los Altos, CA

Learn more about the CED Life Science Conference.